ABBVIE (ABBV) Earnings Date & Reports

Key Takeaways

• AbbVie reports second-quarter 2026 results on Friday, July 31, before the market opens, with the company guiding for adjusted earnings per share (EPS) between $3.74 and $3.78.
• Consensus revenue estimates hover near $16.8 billion, representing year-over-year growth of approximately 9%, driven largely by the immunology portfolio.
• Skyrizi and Rinvoq remain the central growth narrative, with consensus sales estimates of roughly $5.49 billion and $2.47 billion, respectively, as both drugs continue gaining market share across multiple indications.
• Legacy Humira sales are expected to keep declining, with consensus estimates near $744 million for the quarter, as biosimilar competition continues eroding the once-dominant blockbuster.
• Analyst sentiment is broadly constructive but measured, with a consensus "Moderate Buy" rating and an average price target around $267, though some firms highlight valuation concerns following the stock's strong run.

Earnings Context and Why It Matters

AbbVie's second-quarter 2026 earnings arrive at a pivotal moment for the North Chicago-based biopharmaceutical giant. Since losing U.S. exclusivity for Humira in 2023, the company has staked its growth thesis on next-generation immunology drugs Skyrizi and Rinvoq. The strategy has gained traction: in Q1 2026, AbbVie delivered a 12.4% year-over-year revenue increase to $15 billion and beat EPS estimates. This quarter will test whether that momentum is durable. With immunology contributing nearly half of total revenue, investors and analysts will scrutinize prescription trends, market share gains, and margin performance across the portfolio. The results will also set expectations for the remainder of fiscal 2026.

Earnings Expectations

Wall Street expects AbbVie to report adjusted EPS in the range of approximately $3.74 to $3.79 for the second quarter of 2026, which would mark a roughly 26% to 28% increase from the $2.97 reported in the same period a year ago. The company's own guidance, issued alongside its Q1 2026 results, calls for adjusted EPS of $3.74 to $3.78 on revenue of approximately $16.7 billion. Consensus revenue estimates stand slightly higher at around $16.77 billion to $16.8 billion.

The primary focus will be on AbbVie's immunology franchise. Skyrizi, approved across psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, carries a consensus sales estimate of roughly $5.49 billion for Q2. Rinvoq, which spans rheumatoid arthritis, atopic dermatitis, and inflammatory bowel disease indications, is expected to generate approximately $2.47 billion. Together, these two therapies are forecast to more than offset Humira's ongoing erosion. AbbVie has beaten EPS estimates in each of its last four quarterly reports, and another outperformance in Q2 could reinforce confidence in the post-Humira growth story. Key metrics to monitor beyond top-line figures include operating margin trends, neuroscience franchise performance, and updates on the aesthetics portfolio through Allergan Aesthetics.

AI Screener

For investors looking to track earnings season opportunities and identify stocks with strong momentum patterns ahead of key events like AbbVie's Q2 report, Tickeron's AI Screener offers a powerful, data-driven solution. The AI Screener is an AI-powered stock and ETF discovery tool that enables traders and investors to filter thousands of securities based on technical patterns, fundamental metrics, volatility profiles, trend strength, and proprietary AI-driven signals. Users can customize searches by industry, market capitalization, technical indicators, price patterns, and performance metrics to surface trade ideas, breakout candidates, and trending stocks far more efficiently than through traditional manual screening. Exploring the screener ahead of major earnings announcements can help you identify actionable patterns in the broader pharmaceutical and healthcare landscape.

Market Reaction and Investor Sentiment

Sentiment heading into AbbVie's Q2 2026 report is cautiously optimistic. The stock has rallied significantly from its 52-week low of $184.63, recently trading above $250 per share and approaching its 52-week high of $261.64. Multiple Wall Street firms, including Wells Fargo, Piper Sandler, Bank of America, and HSBC, have raised price targets in recent weeks, reflecting confidence in the immunology portfolio. However, some caution exists: Citi and UBS maintained neutral ratings while raising targets to $260, and valuation-focused analysts point to an elevated trailing price-to-earnings (P/E) ratio that sits well above the company's five-year median. Zacks has assigned ABBV a Rank #4 (Sell), citing slight downward revisions to consensus EPS estimates over the past month. The stock's relatively low beta of 0.30 suggests it tends to be less volatile than the broader market, but earnings day could produce outsized moves if reported Skyrizi or Rinvoq sales deviate meaningfully from consensus.

Forward Outlook and Key Factors to Monitor

Beyond the second-quarter headline numbers, several factors will shape AbbVie's trajectory through the remainder of 2026 and into 2027.

First, the immunology growth runway remains the single most important driver. Skyrizi and Rinvoq are still expanding into new indications, and regulatory developments — including recent submissions for Rinvoq in severe alopecia areata and a subcutaneous induction option for Skyrizi in Crohn's disease — could unlock additional patient populations. Investors should listen closely for management commentary on prescription trends, market access dynamics, and competitive positioning against emerging therapies.

Second, the neuroscience franchise is gaining attention. AbbVie's portfolio in this area, including treatments for Parkinson's disease and migraine, represents a growing, albeit smaller, contributor. Any updates on pipeline assets or commercial momentum in neuroscience could influence sentiment.

Third, cost management and margin trajectory will be under the microscope. With Humira revenue declining and the company still absorbing acquisition-related costs, operating efficiency remains critical. The Q2 report will provide insight into whether AbbVie can sustain margin expansion while investing in its pipeline and commercial infrastructure.

Finally, macroeconomic and policy considerations — including pricing regulation debates and interest rate expectations — could affect how pharmaceutical stocks are valued in the near term. AbbVie's dividend, currently yielding approximately 2.7% on an annualized basis, continues to appeal to income-oriented investors, but payout sustainability depends on durable free cash flow generation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations